Jefferies analyst David Steinberg raised his price target for Aclaris Therapeutics (ACRS) to $33 from $30 after the company acquired Rhofade from Allergan (AGN). As Allergan has already done much of the "heavy lifting" for the launch, and the product leverages Aclaris' current sales force, Rhofade should be accretive to EBITDA in Q4 of 2019, Steinberg tells investors in a research note. The analyst believes the drug is potentially a best in class product for skin condition rosacea. He thinks peak sales could conservatively reach $60M and keeps a Buy rating on Aclaris Therapeutics.